ED as an Early Predictor of Heart Attack Risk

A man's first heart attack often arrives with no warning at all. Ask a room of medical students what usually happens right before someone's first heart attack, and the textbook answer is unsettling: nothing. No chest pain, no shortness of breath, just a body that seemed fine until it wasn't. That gap in the warning system is why Mayo Clinic urologist Tobias Kohler keeps steering the conversation toward an organ cardiologists rarely mention: the penis.

"The check engine light, the canary in the coal mine" - Tobias Kohler [00:59]

The logic, Kohler explains, is plumbing. An erection needs healthy blood vessels, working nerves, and balanced hormones all at once. When the body is under stress or getting sick, it redirects blood toward the brain and away from less urgent business (00:59). So if the plumbing fails in the bedroom before it fails anywhere else noticeable, that failure is data. It is why the Princeton IV Consensus Guidelines, a set of recommendations written by a mixed panel of cardiologists, urologists, and endocrinologists that Kohler co-chairs, now treat erectile dysfunction as a cardiac symptom rather than a private inconvenience (10:36).

"The most effective predictor of having a heart attack that we have is erectile dysfunction, especially in younger men" - Tobias Kohler [11:11]

The guidelines translate that finding into something concrete: a young man with new erectile trouble should strongly consider a coronary calcium score, a CT scan that measures hardened plaque in the heart's arteries years before a heart attack might happen (11:59). Cialis, one of the standard erectile dysfunction pills, may also carry a cardioprotective effect on top of its usual job, though Kohler is careful to say the evidence there is still developing (11:59).

The Ceramide Clue

Standard cholesterol panels have a known blind spot: plenty of people with normal cholesterol still have heart attacks (24:43). Kohler's answer to that gap is a newer blood test built around ceramides, a ubiquitous protein already familiar to anyone who reads a lotion label, because certain ceramides also mark inflammation in the lining of blood vessels near the heart (12:49). Mayo Clinic has built a specific version of the test, scored from zero to twelve, where a twelve means, in Kohler's words, you are going to the cardiologist tomorrow (13:48). What makes the test unusual is its speed. Cholesterol numbers move slowly and do not react quickly to a new gym habit. Ceramide scores do. Kohler says patients who clean up their diet and start exercising can see the number drop within weeks, which turns the test into feedback rather than just a diagnosis (15:12).

That same conversation exposed a limit of the standard cholesterol playbook. Preventive cardiologist Dr. Kopetsky, a mentor Kohler cites throughout the episode, argues that everyone starts life with an LDL cholesterol level around 50 milligrams per deciliter (mg/dL), and that anyone who has already had a heart attack or shows plaque on a scan should aim to get back down there (23:15). The more familiar guideline threshold, an LDL above 130 mg/dL affecting roughly a quarter of the population, is a population-level trigger for dietary intervention, not a personal optimum (24:21). For someone with no cardiac history, Kopetsky's target is 100 mg/dL, still double the birth level but far below where most adults sit before treatment (25:01). On a related worry, Kohler says he has not seen convincing evidence that statins meaningfully lower testosterone, and notes that people who take statins actually show lower rates of dementia, not higher (22:54).

What Happens When Testosterone Runs Too Hot

Testosterone, Kohler says, behaves like most things in physiology: too little is bad, there is a healthy range, and past a certain point the body starts to break. A normal adult male level sits around 500 nanograms per deciliter (ng/dL); the guidelines say to aim for around that level, and Kohler notes that anything near 1,000 ng/dL, achieved naturally by very few men, is a reasonable upper limit from his own perspective (30:16). The trouble starts well above that, in the range of 2,000 to 3,000 ng/dL that some men chase through unsupervised, high-dose use (29:26). At that level, Kohler says, cardiovascular disease risk rises clearly, largely because the heart itself changes shape and its electrical wiring changes with it, which is why sudden arrhythmia, not a classic blocked artery, kills many men who abuse steroids (44:55). Cardiac mortality among certain WrestleMania-era wrestlers ran roughly 100 times higher than the general population, a number Kohler attributes partly to steroid use and partly to the extreme weight swings that followed retirement from training (43:46).

An old, almost forgotten trial from the 1980s complicates the shortcut logic. Researchers gave ordinary men 400-milligram testosterone injections, high enough to push levels near 2,000 ng/dL, and split them into groups: steroids with no training, training with no steroids, both, or neither. On bench press and squat scores, the men who trained without steroids beat the men who took steroids without training (39:25). The lesson Kohler draws is blunt: the exercise stimulus, not the drug, is doing most of the early work, and the real danger of chasing shortcuts is a body that eventually needs ever-higher doses just to feel normal, since men who run testosterone at 2,000 ng/dL for years can develop a new, higher set point and feel awful at what used to be a healthy level (37:08).

The same vascular story shows up lower down. Peyronie's disease, a condition where scar tissue makes the penis curve, often starts as a repeated microtrauma from attempting sex with an erection that was not quite firm enough to withstand the friction (54:10). Kohler's practical advice to men prone to it, including those with connective tissue conditions like Dupuytren's contracture, is straightforward: aim for full, reliable erections during sex rather than pushing through partial ones (55:38).

For men recovering from a radical prostatectomy, a surgery to remove the prostate for cancer, that same vascular fragility becomes the whole story. The nerves and blood vessels that serve the penis sit right next to the prostate, and removing the gland often damages one or both (63:10). Kohler lays out recovery as a ladder: pills first, then a vacuum device to stretch and preserve length, then injectable medication if pills fail, and only after a year, if nothing else works and the patient wants it, a penile implant (62:45). Roughly a quarter to half of men recover enough to manage with pills alone, better odds for younger men who had strong erections and less cardiovascular disease going in (66:00). Kohler's closing advice for anyone facing a major diagnosis is to lean on the people around them, because a patient absorbed in fear about cancer rarely remembers to ask about fertility preservation or sexual rehabilitation on their own (66:21).

The episode ends on an anecdote that undercuts the whole premise of chasing testosterone in the first place. A physical therapist at Mayo Clinic with advanced prostate cancer was terrified that hormone-deprivation therapy would strip his muscle. Kohler told him to keep lifting anyway. Two months later, with testosterone near zero, the man was hitting personal records he had never hit before, apparently because clearing his cancer's inflammatory burden freed up resources his body had been diverting elsewhere (69:24). It is a strange, hopeful footnote to an episode mostly about warning signs: sometimes the body's capacity is larger than the story a single hormone number seems to tell.